Thursday 16 October, 2025
Objectives: Weight gain is common following antiretroviral therapy (ART) initiation, especially during the first years, and might be associated with an…
Read morePoster: Drug/Disease Modelling - Infection
Sensitivity analysis of a two-state bacterial model for prediction of clinical short-term bactericidal efficacy in tuberculosis: GSK3036656 case study
Thursday 16 October, 2025
Objectives: GSK3036656 is a potent anti-tuberculosis (TB) drug with a novel mechanism of action, currently being investigated in Phase 2…
Read moreAntibiotic Efficacy during Spaceflight: Impact of Simulated Microgravity on Killing of S. pneumoniae by Ciprofloxacin
Thursday 16 October, 2025
Objectives: To explore the effects of the microgravity environment observed during spaceflight on the killing of S. pneumoniae by ciprofloxacin…
Read moreMechanistic modelling of primaquine pharmacokinetics, gametocyte clearance, and mosquito infectivity
Thursday 16 October, 2025
Objective: Primaquine is the only antimalarial drug targeting the sexual stage of Plasmodium falciparum, gametocytes, which are responsible for the…
Read morePiperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy
Thursday 16 October, 2025
Objective: Pregnant women are at higher risk of Plasmodium falciparum infection and pregnancy-specific adverse effects. The parasites can sequester in…
Read moreDynamical modeling of phage therapy using in vitro and in vivo preclinical data
Thursday 16 October, 2025
Objectives: The emergence of multi-drug resistant (MDR) pathogens is one of the greatest threats to global health. The pipeline of…
Read moreModelling the dose-effect relationship between DAV132, an activated charcoal based product, and fecal concentration of moxifloxacin in healthy volunteers
Thursday 16 October, 2025
Objectives: The administration of antibiotics leads to disruption of the intestinal microbiota, which plays an important role in various host processes,…
Read morePre-clinical Population PK Model of CF-301 – a Novel Antibacterial Lysin
Thursday 16 October, 2025
Background: CF-301 is a lysin with rapid S. aureus-specific bacteriolysis that completed Phase 1 trial [1]. Objectives: To develop a…
Read moreModelling humoral immune response after a single RSV vaccination in RSV-seropositive adults aged 60 and older
Thursday 16 October, 2025
Introduction: Respiratory Syncytial Virus (RSV) is a cause of a considerable number of lower and upper respiratory tract infections, morbidity,…
Read morePopulation pharmacokinetics of KAF156/LUM-SDF and exposure-response analysis for the probability of cure for patients with uncomplicated malaria
Thursday 16 October, 2025
Objectives: To describe the population pharmacokinetics (PK) of KAF156 (KAF) and the solid dispersion formulation of lumefantrine (LUM-SDF) when given…
Read more